妊娠和哺乳相关骨质疏松症的研究进展

妊娠和哺乳相关骨质疏松症是一种罕见的继发性骨质疏松症,通常发生在妊娠晚期和哺乳早期,由于发病率较低及发病时间特殊,相对诊断工具有限,并且大多数文献报道也属个案或对疾病状态的一般描述,因此对其管理与诊断尚未形成指南与共识。由于妊娠和哺乳相关骨质疏松症具有自限性,一部分病人在妊娠和哺乳完成后,骨密度会自发改善,因此如何治疗该病的确凿建议也未明确提出。降钙素、双膦酸盐、地舒单抗和特立帕肽均已用于个体患者,但是治疗效果褒贬不一,也没有大量的客观数据反馈长远治疗效果,因此,对于妊娠和哺乳相关骨质疏松症的探索仍然有待继续,有望在未来形成共识并开发出更安全的药物进行治疗。

The research progress in pregnancy and lactation-related osteoporosis

Pregnancy and lactation related osteoporosis is a rare secondary osteoporosis,which usually occurs in late pregnancy and early lactation. Due to its low incidence and its specific timing, relatively limited diagnostic tools, and the fact that most reports in the literature are case by case or general descriptions of the disease state, guidelines and consensus for its management and diagnosis have not been developed. Due to the self-limiting nature of pregnancy and lactation-related osteoporosis, some patients experience spontaneous improvement in bone mineral density after pregnancy and lactation. Therefore, firm recommendations on how to treat patients with this disease have not been clearly formulated, and Calcitonin, Bisphosphonates, Desuzumab and Teriparatide have all been used in individual patients, but the results of treatment have been mixed and there is no extensive objective data to provide feedback on the long-term effects of treatment; therefore, the exploration of Pregnancy and lactation-related osteoporosis remains to be continued, and it is expected that a consensus will be formed and safer drugs will be developed to treat this disease in the future.